Intracellular potentiation of cAMP has recently garnered renewed interest as an antifibrotic therapy in IPF and non‐IPF pulmonary fibrosis following the promising phase 3 results of the PDE inhibitor nerandomilast [54, 55]. The gene discussed is ALDH7A1; the disease is pulmonary fibrosis.